Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an announcement.
Radiopharm Theranostics Limited announced that Point72 Asset Management, L.P. has ceased to hold a long equity derivative position of 5% or more in the company’s ordinary shares as of October 27, 2025. This change in equity position, disclosed under the Australian Takeovers Panel Guidance Note 20, indicates a reduction in Point72’s investment in Radiopharm, potentially impacting the company’s shareholder structure and market perception.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is positioned in the market to leverage advanced technologies in nuclear medicine to address various health conditions.
Average Trading Volume: 6,058,322
Technical Sentiment Signal: Sell
Current Market Cap: A$66.74M
Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.